EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington’s Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis

Lautaro Manuel Floridia Rietmann iD, Candela Romano iD, Salma Alejandra Beltrán Covarrubias, Jose Antonio Gomez Miranda iD, Omar Enrique Briceño Cardeña iD, Shwetha Shenod iD, Ada Victoria Marrero Peralta iD, Genesis Mariana Ferrer Zavala iD, Prasanth Hanumanthu, Omar Borges Sosa, Ernesto Calderon Martinez iD

Medical Sciences · 22.09.2025 · 13 (3) · 201

DOI: 10.3390/medsci13030201 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Medical Sciences, online erschienen am 22.09.2025. Verfasst von Lautaro Manuel Floridia Rietmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Ciencias Médicas, Universidad Nacional del Litoral, Santa Fe 3000, Argentina. Hauptthemen laut MEDLINE: Huntington Disease, Vesicular Monoamine Transport Proteins, Dopamine Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Huntington’s disease (HD) causes progressive motor dysfunction, with chorea as its hallmark symptom. Vesicular monoamine transporter 2 (VMAT 2) inhibitors (tetrabenazine, deutetrabenazine, valbenazine) are established symptomatic therapies, while dopamine stabilizers (pridopidine, ordopidine) are emerging therapies, but their net benefit and safety remain uncertain.

Methods

Seven databases were searched through May 2025 following PRISMA guidelines. Random effects meta-analyses calculated mean differences (MDs) for the Unified Huntington Disease Rating Scale total motor score (UHDRS TMS) and total maximal chorea score (TMC), plus risk ratios (RRs) for adverse events (AEs). Trial Sequential Analysis (TSA) applied a Lan DeMets O’Brien Fleming α spending function with 80% power.

Results

Seven randomized trials (1431 participants) met inclusion criteria. VMAT 2 inhibitors significantly improved motor outcomes versus placebo (UHDRS TMS: MD −3.80, 95% CI −5.76 to −1.83; TMC: MD −3.05, 95% CI −3.84 to −2.26; both I2 = 0%). Dopamine stabilizers produced no meaningful change (UHDRS TMS: MD −0.98, 95% CI −2.48 to 0.51; I2 = 32%). Neither class increased total AEs (VMAT 2: RR 1.21, 95% CI 0.99 to 1.48; dopamine stabilizers: RR 1.05, 95% CI 0.92 to 1.20; both I2 = 0%). TSA confirmed robust evidence for VMAT 2 benefits on TMC but indicated additional data are required to verify dopamine stabilizer effects on UHDRS TMS. Trial sequential analysis confirmed the reliability of VMAT2 for TMC; however, the sample size was insufficient to draw conclusions about the effects of dopamine stabilizers on UHDRS TMS or their safety outcomes, indicating that additional data are needed.

Conclusions

VMAT-2 inhibitors may suggest potential improvements in motor symptoms in Huntington’s disease, while current evidence does not demonstrate a significant benefit of dopamine stabilizers. The safety profiles of both treatments appear generally comparable to placebo. Further rigorous and long-term studies are required to better establish their efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseVesicular Monoamine Transport ProteinsDopamine AgentsHumansTetrabenazineRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Huntington’s diseasechoreaefficacymeta-analysispridopidinesafetytetrabenazine

Substanzen

Vesicular Monoamine Transport ProteinsSLC18A2 protein, humanTetrabenazineDopamine Agents

Autor:innen und Institutionen

  • Facultad de Ciencias Médicas, Universidad Nacional del Litoral, Santa Fe 3000, Argentina.
  • Department of Pediatrics, University of California, Irvine, CA 92697, USA.
  • Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
  • Facultad de Medicina, Universidad del del Salvador, San Salvador 1101, El Salvador.
  • Facultad de Medicina, Universidad Autónoma de Yucatán, Mérida 97000, Mexico.
  • PSG Institute of Medical Sciences & Research, Coimbatore 641004, India.

ORCID-Profile: Lautaro Manuel Floridia Rietmann, Candela Romano, Jose Antonio Gomez Miranda, Omar Enrique Briceño Cardeña, Shwetha Shenod, Ada Victoria Marrero Peralta, Genesis Mariana Ferrer Zavala, Ernesto Calderon Martinez

Zitieren

APA

Floridia Rietmann, L. M., Romano, C., Beltrán Covarrubias, S. A., Gomez Miranda, J. A., Briceño Cardeña, O. E., Shenod, S., Marrero Peralta, A. V., Ferrer Zavala, G. M., Hanumanthu, P., Borges Sosa, O., & Calderon Martinez, E. (2025). Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington’s Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. Medical Sciences, 13(3), 201. https://doi.org/10.3390/medsci13030201

Vancouver

Floridia Rietmann LM, Romano C, Beltrán Covarrubias SA, Gomez Miranda JA, Briceño Cardeña OE, Shenod S, et al. Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington’s Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. Medical Sciences. 2025;13(3):201. doi:10.3390/medsci13030201

BibTeX
@article{FloridiaRietmann2025,
  author = {Floridia Rietmann, Lautaro Manuel and Romano, Candela and Beltrán Covarrubias, Salma Alejandra and Gomez Miranda, Jose Antonio and Briceño Cardeña, Omar Enrique and Shenod, Shwetha and Marrero Peralta, Ada Victoria and Ferrer Zavala, Genesis Mariana and Hanumanthu, Prasanth and Borges Sosa, Omar and Calderon Martinez, Ernesto},
  title = {Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington’s Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis},
  journal = {Medical Sciences},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {201},
  doi = {10.3390/medsci13030201}
}
Kostenlos starten →